Ibandronate (Sodium)

CAT: 0804-HY-B0515B-01Size: 50 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0515B-01Size:50 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ibandronate Sodium is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase) . Ibandronate Sodium can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) [1][2][3][4].
CAS Number
[138844-81-2]
UNSPSC
12352211
Hazard Statement
H302-H314-H373-H410
Target
Apoptosis
Type
Reference compound
Related Pathways
Apoptosis
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/ibandronate-sodium.html
Purity
97.00
Solubility
10 mM in H2O
Smiles
OC(P(O)(O)=O)(P(O)([O-])=O)CCN(C)CCCCC.[Na+]
Molecular Formula
C9H22NNaO7P2
Molecular Weight
341.21
Precautions
P260-P264-P270-P273-P280-P301+P330+P331-P303+P361+P353-P304+P340-P305+P351+P338-P330-P363-P391-P405-P501
References & Citations
[1]Journe F, et al. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res. 2006;8 (1) :R2.|[2]Thaler R, et al. Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol. 2013 Jan 15;85 (2) :173-85.|[3]Pfister T, et al. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003 Sep 30;191 (2-3) :159-67.|[4]Russell RG. Ibandronate: pharmacology and preclinical studies. Bone. 2006 Apr;38 (4 Suppl 1) :S7-12.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName
HY-166088Myristelaidate (sodium)
HY-N15194AInostamycin A (sodium)
HY-153496ASepofarsen (sodium)
HY-W088065-01Sodium formate
HY-153497AVupanorsen (sodium)
HY-B0497ANiclosamide (sodium)
HY-120160ADarglitazone (Sodium)
HY-B0144BPitavastatin (sodium)
HY-W099570-01Stearate (sodium)
HY-153484A-01Bevasiranib (sodium)

Alternative Products

CatalogName
M11612-01Ibandronate sodium
452140-01Ibandronate Sodium Salt
TRC-I120001-50MGIbandronate Sodium Monohydrate
A11870-100Ibandronate sodium 100mg
A11870-500Ibandronate sodium 500mg
A11870-1000Ibandronate sodium 1000mg

Popular Products